Joel D. Pearson

980 total citations
16 papers, 338 citations indexed

About

Joel D. Pearson is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Joel D. Pearson has authored 16 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Joel D. Pearson's work include Lymphoma Diagnosis and Treatment (4 papers), Cancer-related Molecular Pathways (3 papers) and T-cell and Retrovirus Studies (2 papers). Joel D. Pearson is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Cancer-related Molecular Pathways (3 papers) and T-cell and Retrovirus Studies (2 papers). Joel D. Pearson collaborates with scholars based in Canada, United States and China. Joel D. Pearson's co-authors include Robert J. Ingham, James Koropatnick, Raymond Lai, Julinor Bacani, Rod Bremner, Jason K. H. Lee, Yupo Ma, Alana L. Welm, Vishnu Kumarasamy and Jianxin Wang and has published in prestigious journals such as Nature, Oncogene and Scientific Reports.

In The Last Decade

Joel D. Pearson

15 papers receiving 331 citations

Peers

Joel D. Pearson

ONCOL

PRM

PFM

IMMUN

Laurène Froment Switzerland

S. Majewski Poland

Laura Mannarino Italy

Cyril Maire France

C S Johnson United States

Kyo Sasaki Japan

Jie Xia China

Gengqiu Luo China

Piotr Łacina Poland

Qifeng Ding China

Laurène Froment Switzerland

Joel D. Pearson

182 ×1.2

179 ×1.2

ONCOL

141 ×1.6

PRM

18 ×0.3

PFM

38 ×0.7

IMMUN

Citations per year, relative to Joel D. Pearson Joel D. Pearson (= 1×) peers Laurène Froment

Countries citing papers authored by Joel D. Pearson

Since Specialization

Citations

This map shows the geographic impact of Joel D. Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel D. Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel D. Pearson more than expected).

Fields of papers citing papers by Joel D. Pearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel D. Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel D. Pearson. The network helps show where Joel D. Pearson may publish in the future.

Co-authorship network of co-authors of Joel D. Pearson

This figure shows the co-authorship network connecting the top 25 collaborators of Joel D. Pearson. A scholar is included among the top collaborators of Joel D. Pearson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel D. Pearson. Joel D. Pearson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Chen, Danian, Suying Lü, Katherine Huang, et al.. (2025). Cell cycle duration determines oncogenic transformation capacity. Nature. 641(8065). 1309–1318. 3 indexed citations

Pires, Layla, Brian C. Wilson, Rod Bremner, et al.. (2022). Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2. Scientific Reports. 12(1). 14438–14438. 16 indexed citations

Knudsen, Erik S., Vishnu Kumarasamy, Ram Nambiar, et al.. (2022). CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Reports. 38(9). 110448–110448. 78 indexed citations

Pearson, Joel D. & Rod Bremner. (2021). Lentiviral-mediated ectopic expression of YAP and TAZ in YAPoff cancer cell lines. STAR Protocols. 2(4). 100870–100870. 3 indexed citations

Pearson, Joel D. & Rod Bremner. (2021). Simplifying cancer: binary pan-cancer superclasses stratified by opposite YAP/TEAD effects. Molecular & Cellular Oncology. 8(5). 1981111–1981111. 2 indexed citations

Song, Ling, Jessica Weiss, Kevin C. Nixon, et al.. (2021). The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 111(3). e467–e467. 1 indexed citations

Pearson, Joel D., Katherine Huang, Izhar Livne‐Bar, et al.. (2020). Functional genomics identifies new synergistic therapies for retinoblastoma. Oncogene. 39(31). 5338–5357. 28 indexed citations

Pearson, Joel D., et al.. (2014). Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs. Molecular Cancer. 13(1). 199–199. 11 indexed citations

Pearson, Joel D.. (2013). Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. University of Alberta Library.

10.

Wu, Fang, Jingdong Zhang, Peng Wang, et al.. (2012). Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cellular Signalling. 24(11). 1989–1998. 42 indexed citations

11.

Gélébart, Pascal, Mona Anand, David Sharon, et al.. (2012). Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma. Blood Cancer Journal. 2(8). e82–e82. 32 indexed citations

12.

Pearson, Joel D., Jason K. H. Lee, Julinor Bacani, Raymond Lai, & Robert J. Ingham. (2012). NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. PubMed. 2012. 1–14. 35 indexed citations

13.

Pearson, Joel D., Jason K. H. Lee, Julinor Bacani, Raymond Lai, & Robert J. Ingham. (2011). NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.. PubMed. 4(2). 124–33. 20 indexed citations

14.

Alford, Spencer C., Joel D. Pearson, Amanda Carette, Robert J. Ingham, & Perry L. Howard. (2009). alpha-Sarcin catalytic activity is not required for cytotoxicity. BMC Biochemistry. 10(1). 9–9. 21 indexed citations

15.

Koropatnick, James & Joel D. Pearson. (1993). Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein.. Molecular Pharmacology. 44(1). 44–50. 24 indexed citations

16.

Koropatnick, James & Joel D. Pearson. (1990). Zinc treatment, metallothionein expression, and resistance to cisplatin in mouse melanoma cells. Somatic Cell and Molecular Genetics. 16(6). 529–537. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact